Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXRα signalling pathway in oxLDL-loaded macrophages

Xiaoyang Xu a, b, #, Aolin Zhang a, #, Matthew S. Halquist c, Xinxiu Yuan a, Scott C. Henderson d, William L. Dewey a, Pin-Lan Li a, Ningjun Li a, Fan Zhang a, *

a Department of Pharmacology & Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
b Department of Physiology, Guangzhou Medical University, Guangzhou, China
c Department of Pharmaceutics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
d Department of Anatomy & Neurobiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA

Keywords: simvastatin • lysosomes • unesterified cholesterol • macrophages • NPC1 • LXRα • CYP7A1

Received: June 11, 2016; Accepted: August 9, 2016

Abstract

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the first-line medications prescribed for the prevention and treatment of coronary artery diseases. The efficacy of statins has been attributed not only to their systemic cholesterol-lowering actions but also to their pleiotropic effects that are unrelated to cholesterol reduction. These pleiotropic effects have been increasingly recognized as essential in statins therapy. This study was designed to investigate the pleiotropic actions of simvastatin, one of the most commonly prescribed statins, on macrophage cholesterol homeostasis with a focus on lysosomal free cholesterol egression. With simultaneous nile red and filipin staining, analysis of confocal/multi-photon imaging demonstrated that simvastatin markedly attenuated unesterified (free) cholesterol buildup in macrophages loaded with oxidized low-density lipoprotein but had little effect in reducing the sizes of cholesteryl ester-containing lipid droplets; the reduction in free cholesterol was mainly attributed to decreases in lysosome-compartmentalized cholesterol. Functionally, the egression of free cholesterol from lysosomes attenuated pro-inflammatory cytokine secretion. It was determined that the reduction of lysosomal free cholesterol buildup by simvastatin was due to the up-regulation of Niemann-Pick C1 (NPC1), a lysosomal residing cholesterol transporter. Moreover, the enhanced enzymatic production of 7-hydroxycholesterol by cytochrome P450 7A1 and the subsequent activation of liver X receptor α underscored the up-regulation of NPC1. These findings reveal a novel pleiotropic effect of simvastatin in affecting lysosomal cholesterol efflux in macrophages and the associated significance in the treatment of atherosclerosis.

Introduction

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the first-line medications prescribed for prevention and treatment of coronary artery diseases [1]. Statins work by inhibiting hepatic cholesterol synthesis and up-regulating hepatocyte low-density lipoprotein (LDL) receptors. These actions promote LDL uptake and reduce blood LDL cholesterol levels (LDL-C), thereby stemming cardiovascular events. Beyond this cholesterol-lowering effect, statins have been also found to induce an array of pleiotropic actions on several aspects of atherogenic process, which is unrelated to cholesterol reduction, and these actions are being increasingly recognized as essentials to statins’ efficacy [2–6]. Among these pleiotropic benefits, the stabilization of atherosclerotic plaques and reduction of inflammation could be closely associated with affecting lesional macrophages.

In atherosclerosis, lesional macrophages take up oxidized LDL (oxLDL) and endocytically deliver it to lysosomes, where the oxLDL is hydrolysed to unesterified (free) cholesterol by lysosomal acid lipase. Under normal circumstances, the free cholesterol could be actively transported out of lysosomes—presumably by the Niemann-Pick C1 (NPC1) [7, 8]—and then trafficked either to the endoplasmic...
reticulum (ER) for esterification and stored as lipid droplets or to the plasma membrane as building blocks, or out of the cell in cases of excess abundance [9, 10]. However, when aberrations in cholesterol metabolism and trafficking occur, both cholesteryl ester and free cholesterol could accumulate in the cell. The buildup of cholesteryl ester as lipid droplets renders a foamy macrophage morphology and contributes to the growth of atherosclerotic plaques, and the accumulation of free cholesterol, especially those compartmentalized in lysosomes, has been found to inflict inflammation, one of the major compounding factors in the pathology of atherosclerosis [11]. It has been reported that lysosomes filled with free cholesterol are prone to leakage and the release of cathepsins that can elicit cytoplasm deterioration and macrophage necrosis. Moreover, sequestered cholesterol may prevent lysosomes from taking in cholesterol as lipid droplets, thereby transforming into a foamy macrophage morphology and the accumulation of free cholesterol trafficking, the regulation of free cholesterol trafficking out of lysosomes could be a centrally important pleiotropic mechanism by which statins reduce cardiovascular incidents. In this study, we investigated the pleiotropic actions of simvastatin, one of the most commonly prescribed classes of statins, on cholesterol homeostasis in macrophages with a focus on lysosomal free cholesterol. We found that simvastatin enhanced NPC1 expression and promoted lysosome-compartmentalized free cholesterol efflux, which led to reductions in inflammatory factor secretion in oxLDL-loaded macrophages. The up-regulation of NPC1 was associated with increased production of 7-hydroxycholesterol by cytochrome P450 7A1 (CYP7A1) and subsequent activation of the liver X receptor α (LXRα) signalling pathway.

Materials and methods

All treatment and analysis reagents and biochemical kits utilized in this study were obtained from commercial sources: Cholesterol quantification kit, simvastatin, progesterone, nile red, filipin and 7β-Hydroxycholesterol (Sigma-Aldrich, St. Louis, MO, USA); anti-NPC1 antibody (EMD Millipore, Billerica, MA, USA); Mouse interleukin (IL)-1 beta/IL-1F2 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA); Generation kit, simvastatin, progesterone, nile red, filipin and 7β-Hydroxycholesterol (Sigma-Aldrich, St. Louis, MO, USA); anti-NPC1 antibody (EMD Millipore, Billerica, MA, USA); Mouse interleukin (IL)-1 beta/IL-1F2 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA); GenMute™ siRNA Transfection Reagent (SignaGen Laboratories, Gaithersburg, MD, USA); oxLDL (TBARS: 29–44 nmoles MDA/mg; Alfa Aesar, Ward Hill, MA, USA); rabbit anti-mouse CD68 antibody (Biosis, Woburn, MA, USA); Alexa fluor 633 goat anti-rat IgG (Life Technologies, Carlsbad, CA, USA); LXRα siRNA, NPC1 siRNA and LAMP-1 rat monoclonal antibody (Santa Cruz Biotechnology, Dallas, TX, USA); cytochrome P450 7A1 siRNA (Origene, Rockville, MD, USA); solid-phase extraction (SPE) column (Silicycle, Quebec, QC, Canada); 22(S)-hydroxycholesterol (D7) (Avanti Polar Lipids, Alabaster, AL, USA); HPLC column, XTerra RP18, 2.1 × 150 mm, 5 μM (Waters Corporation, Milford, MA, USA); and lysosome enrichment kit (Thermo Scientific, Waltham, MA, USA). Cells were collected and processed for real-time PCR analysis using GenMute transfection reagents as described previously [19]. RNA interference efficiency was confirmed using quantitative real-time PCR analysis 48 hrs after transfection. The expression of NPC1 and LXRα after LXRα gene silencing were examined, and the transcriptional levels of LXRα after CYP7A1 gene interference were determined. For the Western blot assay of NPC1, the target bands were visualized and quantified using an Odyssey Imager with the application of infrared fluorescent IRDye 680RD-conjugated secondary antibodies. The specific primer pairs used for the amplification of NPC1, LXRα and CYP7A1 were 5′-CATTGAGGTGTCCCTTCTTC-3′ and 5′-CAGGCTTTCCTC TGAAAGAC-3′, 5′-CAAAGATGCAGGACGGAG-3′ and 5′-GCTGACTCCAA CCTATCC-3′, and 5′-AAACCCCTCAASGGAGATGCT-3′ and 5′-AGSCATA CATCCTTCCGTG-3′, respectively. After gene interference of NPC1, LXRα and CYP7A1, additional treatments, like simvastatin and oxLDL, were applied 24 hrs later.

Simultaneous analysis of lipid droplets and lysosomal free cholesterol with confocal/multi-photon scanning microscopy

The effects of simvastatin on lysosomal cholesterol homeostasis were determined by simultaneous staining of free cholesterol and lipid droplets using filipin and nile red fluorescent dyes, respectively, as well as by immunolabeling lysosomal marker protein LAMP1. Macrophages in 8-well chamber slides, after different treatments, were fixed, permeabilized, and labelled with lysosomal LAMP1 and filipin as described in our previous study [19]. The cells were then briefly incubated with nile red (0.25 μg/ml) for 10 min. and rinsed in PBS once before mounting coverslips for microscopy imaging. Fluorescence images were taken using a multi-photon laser scanning microscope (Zeiss LSM 510 NLO META; Carl Zeiss Microscopy, Thornwood, NY, USA) equipped with a 63×/1.4 NA Plan Achromat oil immersion objective lens. Multi-channel images were collected sequentially to ensure no cross-talk between channels, and the detector offset and gain settings were maintained for all of the images collected. The filters imaged were Alexa Fluor 633 (ex 633 nm/ em 650–710 nm), filipin (ex 740 nm/em 435–485 nm) and nile red (ex
cholesterol quantification kit. Free cholesterol in the isolated lysosomes were measured using a collected and cleansed of OptiPrep with one PBS wash. The total and $145,000^9$ gaga t4 of lysosomes were first collected into a lysosome enrichment buffer, broken down using Dounce homogenizer. After removal of cell debris, the cell homogenates were laid on the top of OptiPrep gradients and centrifuged at 145,000 × g at 4 °C for 2 hrs, the concentrated lysosome portion was collected and cleansed of OptiPrep with one PBS wash. The total and free cholesterol in the isolated lysosomes were measured using a cholesterol quantification kit.

### Lysosome fractionation and cholesterol assay

Lysosomes from macrophages were isolated using a lysosome enrichment kit as in our previous studies [21-23]. In brief, the macrophages were first collected into a lysosome enrichment buffer, broken down using Dounce homogenizer. After removal of cell debris, the cell homogenates were laid on the top of OptiPrep gradients and centrifuged at 145,000 × g at 4 °C for 2 hrs, the concentrated lysosome portion was collected and cleansed of OptiPrep with one PBS wash. The total and free cholesterol in the isolated lysosomes were measured using a cholesterol quantification kit.

### Extraction of oxysterols and free cholesterol and LC-MS/MS assay

Oxysterols in macrophages and free cholesterol from macrophage culture media were extracted using published methods [24]. In brief, macrophages from different treatments in 60 mm dishes were first scraped into PBS and lysed through freezing and thawing using liquid nitrogen. A premixed chloroform/methanol (1:1, v:v) solution was subsequently added. After thorough mixing, the oxysterol-containing organic phase was collected and dried using a nitrogen gas evaporator. The residue was dissolved in a 1 ml ethanol saponification solution containing 0.6 M KOH and 1 mg/ml butylated hydroxytoluene and then hydrolysed at 60 °C for 3 hrs. The hydrolysed oxysterols were extracted with chloroform and eluted with isopropanol/hexane (3:7, v:v) through a silica SPE column. The eluate was dried, reconstituted in methanol/water (95:5, v:v), and subjected to LC-MS/MS. The extraction of free cholesterol from macrophage culture media was conducted in the same manner as that for the extraction of oxysterols from macrophages save that saponification was not used. The identification and quantification of oxysterols were performed using an AB Sciex 4000Qtrap, which utilizes positive electrospray ionization, tandem mass spectrometry, and Analyst® 1.5.2 software (AB Sciex, MA, USA). The sterols were chromatographically resolved using Waters Acquity UPLC and Waters X Terra RP18, 2.1 × 150 mm, 5 μM columns with the application of a mobile phase gradient, created by mixing the mobile phase A (5 mM ammonium acetate in methanol) with B (5 mM ammonium acetate in 15% water and 85% methanol) at a flow rate of 0.250 ml/min.: 100% B from 0 to 2 min., 100% B to 0% from 2 to 15 min., hold at 0% B from 15 to 25 min., and finally re-equilibration for 2 min., for a total run time of 27 min. The sterols were quantified using a linear equation with 1/x weighting that was derived from parallel-generated chromatograms (peak area responses) with mixed standards.

### ELISA quantification of IL-1β secretion from macrophages in culture media

Macrophages were subcultured into 6-well plates at 5 × 10^5 cells/well. Seven different treatments were applied to these cells: Control, simvastatin, progesterone+simvastatin, scrambled siRNA, scrambled siRNA+simvastatin, NPC1 siRNA+simvastatin and LXRa siRNA+simvastatin, in combination with oxLDL. After treatments for 24 hrs, the culture media were collected and centrifuged to removal of cell debris. Interleukin-1β in the media was analysed using an IL-1β ELISA kit according to the manufacturer’s manual and our published study [18]. Chemiluminescent absorbance was measured with a microplate reader at $\lambda$ (nm) = 450 and corrected for background readings at $\lambda$ (nm) = 570. The quantity of IL-1β was obtained using the generated standard curve.

### Statistics

Data were presented as mean ± S.E. Significant differences between and within multiple groups were examined using ANOVA. Student’s t-tests were used to evaluate the significance in differences between two groups of observations. P < 0.05 was considered statistically significant.

### Results

**Simvastatin reduced free cholesterol accumulation in macrophages treated with oxLDL**

To investigate simvastatin’s pleiotropic effects on lysosomal cholesterol accumulation, we first examined oxLDL loading on free cholesterol buildup in lysosomes. We simultaneously applied the lipid dyes nile red and filipin as well as lysosomal marker labelling LAMP1 to visualize free cholesterol compartmentalized in lysosomes and cholesterol ester in cytosolic lipid droplets. Confocal images showed that oxLDL at lower concentration loading (0–25 μg/ml) caused limited free cholesterol accumulation, observed as moderate blue staining by filipin. At higher concentrations (25 up to the tested limit of 100 μg/ml), however, oxLDL caused profound free cholesterol accumulation in lysosomes as evidenced by the colocalization of the blue filipin staining with Alexa fluor 633-labelled LAMP1 (Fig. S1A-D). The oxLDL concentration 40 μg/ml was thus used in this study. The pleiotropic effects of simvastatin on intracellular cholesterol accumulation were examined at 10 μM, a concentration that was commonly used in previous studies [25, 26].

Our confocal imaging results showed that simvastatin significantly reduced lysosomal free cholesterol levels in macrophages loaded with oxLDL, as determined by the intensity of blue filipin staining and colocalization coefficient analysis between filipin and fluor 633-labelled lysosomal LAMP1 (Fig. 1A–D). However, simvastatin alone exhibited only modest effects on the lipid droplets and lysosomal cholesterol when compared with control.

To further confirm the effects of simvastatin in lowering lysosomal cholesterol, we fractionated lysosomes using gradient ultracentrifugation and directly measured cholesterol contents in the lysosomal preparations. Consistent with confocal imaging results, biochemical analyses showed that free cholesterol constituted a
major portion of total cholesterol segregated in lysosomes, and after simvastatin treatment, free cholesterol levels in lysosomes were significantly reduced (Fig. 2).

**Reduction of lysosomal cholesterol accumulation by simvastatin increased cholesterol transport out of macrophages**

It has been reported that LDL endocytosis-derived free cholesterol in lysosomes has three trafficking destinations: to ER for esterification, to the plasma membrane where it could be transported out of the cell and a small fraction to the Golgi apparatus [27]. Since simvastatin reduces lysosomal free cholesterol levels with no significant effects on lipid droplets, it is possible that the reduction in lysosomal cholesterol might be associated with enhanced free cholesterol transport out of cells. We, therefore, proceeded to extract free cholesterol from cell culture media and measure their contents using LC-MS/MS. As expected, LC-MS/MS analysis showed that free cholesterol levels in the culture media from the sim+oxLDL group were significantly higher than those in other groups (in nmol/l/10⁶ cells): 119.38±10.75 versus 27.69±6.28, 72.49±8.86 and 29.50±14.49 in control, oxLDL and simvastatin only groups, respectively (Fig. 3).

**Simvastatin promoted lysosomal free cholesterol egress through up-regulation of NPC1 expression via LXRα**

Niemann-Pick C1 is a free cholesterol transporter residing on late endo/lysosomes that has been found to be responsible for free cholesterol efflux from lysosomes. We, therefore, proceeded to investigate how simvastatin enhanced free cholesterol egression from lysosomes by examining whether simvastatin affected the expression

---

**Fig. 1** Confocal images showed simvastatin reduced lysosomal free cholesterol in macrophages loaded with oxLDL. Macrophages were incubated with oxLDL (40 μg/ml) in the presence of simvastatin (10 μM) for 48 hrs and labelled with nile red (lipid droplets of cholesteryl ester, yellow), filipin (free cholesterol, blue) and LAMP1 antibody (lysosomes, red). Simvastatin markedly reduced filipin blue but had little effect on yellow droplet intensity in oxLDL-loaded macrophages. The overlaid images and colocalization coefficient analysis demonstrated that the reduction of filipin staining was mainly from the decrease of lysosomal compartmentalized cholesterol. Simvastatin alone barely had effects on cellular cholesterol levels, compared with control. (A) Confocal/multi-photon microscopy images from nile red, filipin and LAMP1 staining; (B) summarized intensities from free cholesterol staining by filipin; (C) colocalization coefficient between filipin (free cholesterol) and LAMP1 (lysosomes); and (D) summarized intensities from the staining of lipid droplets (cholesteryl ester). *, # P < 0.05; * versus Ctrl or Sim group, # versus oxLDL group, n = 6. Sim: simvastatin; FC: free cholesterol; CE: cholesteryl ester; Ctrl: control.

© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
of NPC1. RT-qPCR and Western blot results demonstrated that in oxLDL-loaded macrophages, simvastatin elicited significant increases in NPC1 expressions, while oxLDL or simvastatin treatment alone caused only modest changes in NPC1 levels (Fig. 4A–C). While cholesterol is essential for normal cell functioning, excess cholesterol can cause cellular toxicity. Thus, cells have developed exquisite machineries to maintain cholesterol homeostasis. When cholesterol is insufficient in the cell, the nuclear factor Sterol Regulatory Element-Binding Proteins (SREBPs) [28] will be proteolytically activated to promote cholesterol uptake and de novo cholesterol synthesis [29]. In the event of cholesterol excess, however, LXRα will be activated to initiate downstream effectors in enhancing free cholesterol efflux [30]. To elucidate how NPC1 expression was up-regulated by simvastatin, we, therefore, sought to examine the functional role of the transcriptional factor LXRα, one of LXR isoforms highly expressed on macrophages [31]. RT-qPCR analysis indicated that LXRα mRNA had an expression pattern similar to that of NPC1 among the groups control, oxLDL, Sim and Sim+oxLDL (Fig. 5A). Furthermore, after the application of LXRα gene interference, the boosting effects of simvastatin on NPC1 expression were abolished (Fig. 5B and C). These results indicated that simvastatin up-regulated NPC1 expressions in oxLDL-loaded macrophages via LXRα activation.

**Fig. 2** Biochemical measurements showed simvastatin reduced lysosomal cholesterol from oxLDL-loaded macrophages. Lysosomes were fractionated from macrophages incubated with oxLDL in the presence of simvastatin for 48 hrs by gradient ultracentrifuge; the cholesterol in lysosomal preparations was measured with a kit. Homo: macrophage homogenates, free (Total) chol: Free (Total) cholesterol. * P < 0.05; * versus oxLDL in the Homo group, # versus oxLDL in the Lysosome group, n = 4.

**Fig. 3** LC-MS/MS measurement showed simvastatin’s reducing lysosomal cholesterol was associated with elevated secretion of free cholesterol from the cells. Macrophages were incubated with oxLDL at the presence of simvastatin for 48 hrs; the culture media were collected to extract cholesterol for LC-MS/MS assay. (A) Representative MS spectrum graphs of free cholesterol, filled peaks, among different groups; (B) summarized free cholesterol levels in culture media. * P < 0.05; versus any other group, n = 3.
Using fluorescence staining and confocal/multi-photon imaging, we further verified LXRα/NPC1 signalling’s involvement in simvastatin-induced lysosomal free cholesterol efflux. Consistent with simvastatin elevating NPC1 and LXRα expression levels, when NPC1 or LXRα expressions were disrupted by gene interference or when NPC1 was pharmacologically blocked by progesterone (10 μg/ml), simvastatin-induced lysosomal cholesterol efflux was significantly inhibited as indicated by marked increases in the intensity of the blue from filipin’s staining of free cholesterol and an increase in the colocalization coefficient between filipin (blue) and LAMP1 (red) (Fig. 6A–C).

LXRα signalling cascade in simvastatin-induced free cholesterol efflux initiated by 7-hydroxycholesterol

As stated above, LXR signalling serves as a mechanism to promote free cholesterol egression from lysosomes. LXRα is usually activated by elevated production of oxysterols, endogenous LXRα agonists [30]. We, therefore, sought to identify the initiator of the LXRα signalling cascade by examining the expression of cytochrome oxidases responsible for generating oxysterols as well as directly measuring intracellular oxysterol levels. Among the major cytochrome P450 oxidases, CH(25)H, CYP27A1, CYP46A1 and CYP7A1, known to endogenously produce oxysterols, we found that the transcriptional levels of CYP7A1 were markedly increased in macrophages treated with simvastatin and oxLDL (Fig. 7A). Consistently, LC-MS/MS screens showed that levels of cytoplasmic 7-hydroxycholesterol, the enzymatic product of CYP7A1, were markedly elevated in the sim+oxLDL group compared with the oxLDL-only group (in pmole/1 × 10⁶ cells) 374.25 ± 52.77 versus 287.30 ± 66.94 and that 7-hydroxycholesterol was not detectable in control and simvastatin groups. When the CYP7A1 gene was disrupted through siRNA interference, the expressions of LXRα and NPC1 were both reduced (Fig. 7B). Correspondingly, fluorescent imaging results showed that, after CYP7A1 gene disruption, simvastatin-induced lysosomal cholesterol reduction was markedly reduced (Fig. 8A–C); moreover, free cholesterol secretions in culture media of sim+oxLDL-treated cells were significantly attenuated (Fig. 8D).

Fig. 4 Simvastatin increased NPC1 expression in oxLDL-loaded macrophages. Total RNA and protein were extracted 24 and 48 hrs, respectively, from macrophages incubated with oxLDL (40 μg/ml) at the presence of simvastatin (10 μM) to determine the expressions of NPC1. (A) Summarized NPC1 mRNA levels by quantitative RT-PCR analysis, (B) representative W. B. images of NPC1 bands, and (C) summarized intensity from NPC1 bands in W. B., which was normalized to control. *P < 0.05 versus any other group, n = 6 (A), n = 5 (B and C).

Fig. 5 Simvastatin’s up-regulation of NPC1 in oxLDL-loaded macrophages was mediated by LXRα. (A) Quantitative RT-PCR results of LXRα transcriptional levels in macrophages after 24-hr incubation with oxLDL (40 μg/ml) and simvastatin (10 μM), (B) NPC1 band image from W. B. conducted in oxLDL+simvastatin-treated macrophages with LXRα gene interference, (C) Summarized intensity of NPC1 band from W. B., which was normalized to scrambled RNA group. *, # P < 0.05, * versus any other group, # versus Scram; n = 5. Scram: scrambled RNA, si: siRNA.
Suppression of pro-inflammatory cytokine secretion upon reduction of lysosomal free cholesterol accumulation

Accumulated cholesterol in lesional macrophages consists of both free cholesterol and cholesteryl ester. Free cholesterol especially that compartmentalized in lysosomes is cytotoxic and can cause inflammation in atherosclerosis. Therefore, we sought to determine the
The functional significance of simvastatin-induced lysosomal free cholesterol egression in the reduction of inflammation. Direct measurements of IL-1β, a pro-inflammatory cytokine, revealed that the secretion of IL-1β in oxLDL-loaded macrophages was profoundly reduced with simvastatin treatment. Nevertheless, when NPC1 was inhibited by progesterone (10 μg/ml) or disrupted with NPC1 or LXRα siRNA interference, simvastatin-induced IL-1β reduction was abolished (Fig. 9).

Discussion

This study demonstrated that simvastatin up-regulated NPC1 expression and promoted free cholesterol efflux from lysosomes, which led to reductions in inflammation in oxLDL-loaded macrophages. The activation of LXRα through elevated production of 7-hydroxycholesterol by CYP7A1 and consequent up-regulation of NPC1 expression was the underlying mechanism.

Regarding simvastatin’s effects on macrophage cholesterol homeostasis, it has been reported that this cholesterol-lowering agent prevents cholesterol egression in macrophages not loaded with...
oxLDL. This effect can be attributed to a feedback response through SREBPs signalling stemming from insufficient levels of intracellular cholesterol owing to simvastatin’s inhibition of de novo cholesterol synthesis [26, 32]. In oxLDL-unloaded macrophages, we obtained similar results in which simvastatin had only modest effects on free cholesterol efflux. For oxLDL-loaded macrophages, however, we found that simvastatin markedly promoted lysosomal free cholesterol efflux. Thus, oxLDL loading is a necessary condition for simvastatin to exert its cholesterol-egression effects on macrophages. In clinical practice, simvastatin is administered to prevent and treat coronary events. Patients with these conditions have often experienced long-term exposure to hypercholesterolaemia and have been afflicted with advanced atherosclerotic lesions consisting of cholesterol-accumulated macrophages. Given the similarity of cholesterol accumulation in macrophages in vitro and in vivo, it is possible that simvastatin could mobilize cholesterol out of lesional macrophages and exert pleiotropic effects therapeutically.

In this study, we showed that simvastatin had different effects on the cholesterol pools in macrophages. While simvastatin profoundly reduced lysosomal free cholesterol accumulation, it exerted little effect in reducing cytosol cholesterol ester-containing lipid droplets. This finding is consistent with the clinical observation that statins, including simvastatin, generally display limited capacity in reversing the growth of atherosclerotic plaques [33], of which lipid droplets are a major constituent. Since simvastatin had little effect on lipid droplets overall, the reduction in lysosomal free cholesterol may have been associated with an enhancement in cellular cholesterol efflux. Indeed, LC-MS/MS measurement demonstrated that simvastatin markedly increased cholesterol secretions in culture media in oxLDL-loaded macrophages. In this regard, it has been reported that the trafficking of lysosomal free cholesterol to the plasma membrane serves as a major pathway to remove excess cholesterol generated from endocytosed modified LDL [34, 35]. The mechanism underlying the transport of lysosomal cholesterol out of the plasma membrane still remains largely unknown. Nonetheless, simvastatin, by promoting free cholesterol egression from lysosomes, markedly reduces inflammatory cytokine production, an indispensable additional benefit that aids in simvastatin’s prevention and treatment of atherosclerosis.

Regarding how simvastatin promoted lysosomal cholesterol efflux, we found that enhanced expressions of NPC1 underscored this process. In elucidating the pathway that led to NPC1 up-regulation, we examined the signalling role of LXRα, a well-defined nuclear transcription factor that functions to regulate excess cholesterol in cells. By determining the cytoplasmic levels of all major oxysterols, 7-, 22-, 24-, 25- and 27-hydroxycholesterol and desmosterol, known to endogenously activate LXRα, we found that the level of 7-hydroxycholesterol was significantly increased. As expected, the transcription of CYP7A1, the enzyme responsible for 7-hydroxycholesterol production, was also markedly elevated. Disruption of CYP7A1 by siRNA gene interference led to the abolition of LXRα-mediated signalling and its associated free cholesterol egression. In this regard, the role of CYP7A1 in cholesterol homeostasis has been also observed in hepatocytes, in which elevated hepatic CYP7A1 expression and 7-hydroxycholesterol production promote bile acid formation and cholesterol clearance in hypercholesterolaemia [36]. In humans, CYP7A1 deficiency could render a hypercholesterolaemic phenotype and cause cholesterol buildup in the liver [37].

In oxLDL-loaded macrophages, we found the cellular cholesterol levels were markedly increased but the expressions of LXRα and CYP7A1 only modestly elevated. Given the activation of LXRα signalling as a fundamental machinery protecting cells against excess cholesterol, one would expect a significant up-regulation in the expressions of LXRα and CYP7A1 with oxLDL loading. It is noteworthy that in our study, the increased free cholesterol in oxLDL-loaded macrophages is largely confined to the lysosomal compartments, and this lysosomal compartmentalized cholesterol could not be effectively sensed and utilized for oxysterol generation by CYP7A1, the processes known occurred in the ER [38]. Therefore, although excess cholesterol has the potential to up-regulate CYP7A1 expression, its limited availability could eventually compromise the expression of CYP7A1 as observed in this study. Besides up-regulated by cholesterol, the expression of CYPs also could be pharmacologically induced by many medicines [39]. In this regard, it has been found that atorvastatin, one member of statins as simvastatin, acts as an inducer to elevate the expression of CYP7A1 in mice [40]. In oxLDL-loaded macrophages, simvastatin could similarly strengthen the expression of CYP7A1 and boost its enzymatic production of 7α-hydroxycholesterol. The expression of LXRα has been found regulated through an autoregulation mechanism [41], in which the transcriptional activation of LXRα by its ligand oxysterols also leads to the up-regulation of expression in LXRα itself. Thus, in oxLDL-only group, without the presence of simvastatin and the subsequent insufficiency in 7α-hydroxycholesterol, the expression of LXRα could be greatly compromised.

In summary, our results for the first time demonstrate that simvastatin promotes free cholesterol efflux from lysosomes and decreases inflammation in oxLDL-loaded macrophages. These findings will advance our pharmacological knowledge of simvastatin’s lesion-targeted pleiotropic actions in the prevention and treatment of cardiovascular diseases. The findings from this study may also be able to guide us to delineate other satins’ pleiotropic benefits.

Acknowledgements

This work was supported by the National Institute of Health National Heart, Lung, and Blood Institute (grant R01HL115068 to Fan Zhang) and the National Institute of Diabetes and Digestive and Kidney Diseases (grant R01HL89563 to Ningjun Li). Confocal/multi-photon scanning microscopy was performed at the VCU Microscopy Facility, supported, in part, by funding from the NIH-NCI Cancer Center Support Grant P30 CA016059.

Conflict of interest

The authors confirm that there are no conflicts of interest.

Author contribution

F. Zhang designed the research study. Xu, A. Zhang, Halquist, Yuan and F. Zhang performed the research. Xu, Yuan and F. Zhang
performed data analysis. A. Zhang, Halquist, Henderson, Dewey, P-L Li, N. Li and F. Zhang wrote or contributed to the writing of the manuscript.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

References

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2899–934.

2. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999; 10: 543–59.

3. Bellosta S, Ferri N, Arnaboldi L, et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000; 23 (Suppl 2): B72–8.

4. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000; 35: 1–10.

5. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. 2001; 88: 291–3.

6. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001; 49: 281–7.

7. Vanier MT. Complex lipid trafficking in Niemann-Pick disease type C. J Inherit Metab Dis. 2015; 38: 187–99.

8. Pfisterer SG, Peranen J, Ikonen E. LDL-cholesterol transport to the endoplasmic reticulum: current concepts. Curr Opin Lipidol. 2016; 27: 282–7.

9. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983; 52: 223–61.

10. Rothblat GH, de la Llera-Moya M, Atger V, et al. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res. 1999; 40: 781–96.

11. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015; 15: 104–16.

12. Kornfeld S. Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest. 1986; 77: 1–6.

13. Liu J, Sukhova GK, Yang JT, et al. Cather- sin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2006; 184: 302–11.

14. Sukhova GK, Shi GP, Simon DI, et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998; 102: 576–83.

15. Tangirala RK, Jerome WG, Jones NL, et al. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J Lipid Res. 1994; 35: 93–104.

16. Hornung V, Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol. 2010; 40: 620–3.

17. Dueweli P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464: 1357–61.

18. Xu X, Zhang A, Li N, et al. Concentration-dependent diversification effects of free cholesterol loading on macrophage viability and polarization. Cell Physiol Biochem. 2015; 37: 419–31.

19. Xu X, Yuan X, Li N, et al. Lysosomal cholesterol accumulation in macrophages leading to coronary atherosclerosis in CD38 mice. J Cell Mol Med. 2016; 20: 1001–13.

20. Xu X, Yuan X, Li N, et al. Lysosomal cholesterol accumulation in macrophages leading to coronary atherosclerosis in CD38(-/-) mice. J Cell Mol Med. 2016; 20: 1001–13.

21. Zhang F, Xu M, Han WQ, et al. Reconstitution of lysosomal NAADP-TRP-ML1 signaling pathway and its function in TRP-ML1 (+/-) cells. Am J Physiol Cell Physiol. 2011; 301: C421–30.

22. Zhang F, Li PL. Reconstitution and characterization of a nicotinic acid adenine dinucleotide phosphate (NAADP)-sensitive Ca2+ release channel from liver lysosomes of rats. J Biol Chem. 2007; 282: 25259–69.

23. Zhang F, Jin S, Yi F, et al. TRP-ML1 functions as a lysosomal NAADP-sensitive Ca2+ release channel in coronary arterial myocytes. J Cell Mol Med. 2009; 13: 3174–85.

24. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates macrophase lipid metabolism and inflammatory responses. Cell. 2012; 151: 138–52.

25. Tuomisto TT, Lumivuori H, Kansanen E, et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res. 2008; 78: 175–84.

26. Wang W, Song W, Wang Y, et al. HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. J Cardiovasc Pharmacol. 2013; 62: 90–8.

27. Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler Thromb Vasc Biol. 2004; 24: 1150–60.

28. Horten JD, Goldstein JL, Brown MS. SREBP1s: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125–31.

29. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006; 124: 35–46.

30. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003; 17: 985–93.

31. Reja JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000; 16: 459–81.

32. Sone H, Shimano H, Shu M, et al. Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. Biochem Biophys Res Commun. 2004; 316: 790–4.

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
33. Bittencourt MS, Cerci RJ. Statin effects on atherosclerotic plaques: regression or healing? *BMC Med.* 2015; 13: 260.

34. Rigamonti E, Helin L, Lestavel S, et al. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. *Circ Res.* 2005; 97: 682–9.

35. Millard EE, Gale SE, Dudley N, et al. The sterol-sensing domain of the Niemann-Pick C1 (NPC1) protein regulates trafficking of low density lipoprotein cholesterol. *J Biol Chem.* 2005; 280: 28561–90.

36. Lorbek G, Lewinska M, Rozman D. Cytochrome P450s in the synthesis of cholesterol and bile acids—from mouse models to human diseases. *FEBS J.* 2012; 279: 1516–33.

37. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. *J Clin Invest.* 2002; 110: 109–17.

38. Luu W, Sharpe LJ, Capell-Hattam I, et al. Oxysterols: old tale, new twists. *Annu Rev Pharmacol Toxicol.* 2016; 56: 447–67.

39. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. *Lancet.* 2002; 360: 1155–62.

40. Fu ZD, Cui JY, Klaassen CD. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. *J Lipid Res.* 2014; 55: 2576–86.

41. Laffitte BA, Joseph SB, Walczak R, et al. Autoregulation of the human liver X receptor alpha promoter. *Mol Cell Biol.* 2001; 21: 7558–68.